{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:59:26Z","timestamp":1791464366230,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ajog.2021.08.027","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T10:41:39Z","timestamp":1630060899000},"page":"S1145-S1156.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"S","title":["Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction"],"prefix":"10.1016","volume":"226","author":[{"given":"Kelsey","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-8794","authenticated-orcid":false,"given":"Sebastian R.","family":"Hobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4803-3023","authenticated-orcid":false,"given":"Anjana Ravi","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory C.","family":"Windrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-3277","authenticated-orcid":false,"given":"W. Tony","family":"Parks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5729-4631","authenticated-orcid":false,"given":"Adrian W.","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0799-1105","authenticated-orcid":false,"given":"Ulla","family":"Sovio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7411-5535","authenticated-orcid":false,"given":"John C.","family":"Kingdom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2021.08.027_bib1","doi-asserted-by":"crossref","first-page":"H1008","DOI":"10.1152\/ajpheart.00109.2020","article-title":"Low molecular weight heparin promotes transcription and release of placental growth factor from endothelial cells","volume":"318","author":"McLaughlin","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ajog.2021.08.027_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1677\/joe.0.1590459","article-title":"Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation","volume":"159","author":"Clark","year":"1998","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.ajog.2021.08.027_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.116.08620","article-title":"Prediction of preeclampsia using the Soluble fms-Like tyrosine kinase 1 to placental growth factor Ratio: a Prospective Cohort Study of Unselected Nulliparous Women","volume":"69","author":"Sovio","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2021.08.027_bib4","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/HYPERTENSIONAHA.119.13360","article-title":"Predictive performance of PlGF (placental growth factor) for screening preeclampsia in asymptomatic women: a systematic review and meta-analysis","volume":"74","author":"Agrawal","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2021.08.027_bib5","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1161\/CIRCULATIONAHA.113.003215","article-title":"Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study","volume":"128","author":"Chappell","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ajog.2021.08.027_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.placenta.2016.03.010","article-title":"Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction","volume":"42","author":"Benton","year":"2016","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2021.08.027_bib7","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/HYPERTENSIONAHA.121.17047","article-title":"PlGF (Placental growth factor) testing in clinical practice: evidence From a Canadian Tertiary Maternity Referral Center","volume":"77","author":"McLaughlin","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2021.08.027_bib8","doi-asserted-by":"crossref","first-page":"326.e1","DOI":"10.1016\/j.ajog.2006.11.002","article-title":"Identification of patients at risk for early onset and\/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor","volume":"196","author":"Espinoza","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/1471-0528.12195","article-title":"Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study","volume":"120","author":"Myers","year":"2013","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2021.08.027_bib10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus Placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.08.027_bib11","doi-asserted-by":"crossref","first-page":"197.e1","DOI":"10.1016\/j.ajog.2018.10.092","article-title":"Two-stage screening for preterm preeclampsia at 11-13 weeks\u2019 gestation","volume":"220","author":"Wright","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/1471-0528.16361","article-title":"Implementation of routine first trimester combined screening for pre-eclampsia: a clinical effectiveness study","volume":"128","author":"Guy","year":"2021","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2021.08.027_bib13","doi-asserted-by":"crossref","first-page":"585.e1","DOI":"10.1016\/j.ajog.2017.07.038","article-title":"Aspirin for Evidence-Based preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history","volume":"217","author":"Poon","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib14","doi-asserted-by":"crossref","first-page":"S803","DOI":"10.1016\/j.ajog.2017.11.575","article-title":"A\u00a0placenta clinic approach to the diagnosis and management of fetal growth restriction","volume":"218","author":"Kingdom","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib15","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1038\/s41598-017-06178-z","article-title":"Endothelial dysfunction in severe preeclampsia is mediated by soluble factors, rather than extracellular vesicles","volume":"7","author":"O\u2019Brien","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajog.2021.08.027_bib16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ogc.2019.10.008","article-title":"The placental basis of fetal growth restriction","volume":"47","author":"Zur","year":"2020","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.ajog.2021.08.027_bib17","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/biolre\/ioy127","article-title":"Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia","volume":"99","author":"Wat","year":"2018","journal-title":"Biol Reprod"},{"key":"10.1016\/j.ajog.2021.08.027_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/HYPERTENSIONAHA.116.08298","article-title":"Low molecular weight heparin improves endothelial function in pregnant women at high risk of preeclampsia","volume":"69","author":"McLaughlin","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2021.08.027_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.placenta.2014.12.008","article-title":"Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor","volume":"36","author":"Yinon","year":"2015","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2021.08.027_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1161\/01.HYP.0000149950.05182.a3","article-title":"Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women","volume":"45","author":"Mello","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2021.08.027_bib21","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1055\/s-0037-1616738","article-title":"Thromboprophylaxis following caesarean section\u2014a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin","volume":"86","author":"Ellison","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ajog.2021.08.027_bib22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.AOG.0000128902.84876.d4","article-title":"Effects of low-molecular-weight and unfractionated heparin on trophoblast function","volume":"104","author":"Quenby","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib23","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000098952","article-title":"Enoxaparin reduces H2O2-induced activation of human endothelial cells by a mechanism involving cell adhesion molecules and nuclear transcription factors","volume":"79","author":"Manduteanu","year":"2007","journal-title":"Pharmacology"},{"key":"10.1016\/j.ajog.2021.08.027_bib24","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ultrasmedbio.2006.05.030","article-title":"Low-molecular-weight heparin improves the performance of uterine artery Doppler velocimetry to predict preeclampsia and small-for-gestational age infant in women with gestational hypertension","volume":"32","author":"Torricelli","year":"2006","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.ajog.2021.08.027_bib25","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/j.1538-7836.2011.04526.x","article-title":"Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling","volume":"9","author":"Drewlo","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ajog.2021.08.027_bib26","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/bcp.13483","article-title":"Low molecular weight heparin for the prevention of severe preeclampsia: where next?","volume":"84","author":"McLaughlin","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2021.08.027_bib27","article-title":"Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis","author":"Cruz-Lemini","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib28","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.placenta.2016.10.011","article-title":"The pregnancy outcome prediction (POP) study: investigating the relationship between serial prenatal ultrasonography, biomarkers, placental phenotype and adverse pregnancy outcomes","volume":"59","author":"Gaccioli","year":"2017","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2021.08.027_bib29","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/AOG.0000000000002264","article-title":"Maternal vascular malperfusion and adverse perinatal outcomes in low-risk nulliparous women","volume":"130","author":"Wright","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/uog.5315","article-title":"Reference ranges for uterine artery mean pulsatility index at 11-41 weeks of gestation","volume":"32","author":"G\u00f3mez","year":"2008","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib31","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1701-2163(15)30588-0","article-title":"Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary","volume":"36","author":"Magee","year":"2014","journal-title":"J\u00a0Obstet Gynaecol Can"},{"key":"10.1016\/j.ajog.2021.08.027_bib32","first-page":"1122","article-title":"Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists\u2019 Task Force on Hypertension in Pregnancy","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib33","doi-asserted-by":"crossref","first-page":"698","DOI":"10.5858\/arpa.2015-0225-CC","article-title":"Sampling and definitions of placental lesions: Amsterdam placental workshop group consensus statement","volume":"140","author":"Khong","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ajog.2021.08.027_bib34","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/sim.4780111005","article-title":"Smoothing reference centile curves: the LMS method and penalized likelihood","volume":"11","author":"Cole","year":"1992","journal-title":"Stat Med"},{"key":"10.1016\/j.ajog.2021.08.027_bib35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1467-9876.2005.00510.x","article-title":"Generalized additive models for location, scale and shape","volume":"54","author":"Rigby","year":"2005","journal-title":"J\u00a0Royal Statistical Soc C"},{"key":"10.1016\/j.ajog.2021.08.027_bib36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.placenta.2018.04.014","article-title":"Parental ethnicity and placental maternal vascular malperfusion pathology in healthy nulliparous women","volume":"66","author":"Audette","year":"2018","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2021.08.027_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/uog.19051","article-title":"Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study","volume":"53","author":"McCarthy","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib38","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of\u00a0preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.08.027_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.preghy.2011.08.117","article-title":"A\u00a0single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia","volume":"2","author":"Knudsen","year":"2012","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2021.08.027_bib40","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1161\/HYPERTENSIONAHA.113.01787","article-title":"New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1\/placental growth factor ratio as a diagnostic test for preeclampsia","volume":"63","author":"Verlohren","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2021.08.027_bib41","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3109\/14767058.2011.589932","article-title":"Maternal plasma concentrations of angiogenic\/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia","volume":"24","author":"Chaiworapongsa","year":"2011","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2021.08.027_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.preghy.2015.12.002","article-title":"Extending the scope of pooled analyses of individual patient biomarker data from heterogeneous laboratory platforms and cohorts using merging algorithms","volume":"6","author":"Burke","year":"2016","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2021.08.027_bib43","doi-asserted-by":"crossref","first-page":"163.e1","DOI":"10.1016\/j.ajog.2011.09.019","article-title":"Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction?","volume":"206","author":"Benton","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib44","doi-asserted-by":"crossref","first-page":"629.e1","DOI":"10.1016\/j.ajog.2015.11.015","article-title":"Maternal plasma angiogenic index-1 (placental growth factor\/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study","volume":"214","author":"Korzeniewski","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib45","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/HYPERTENSIONAHA.120.14701","article-title":"T2\u2217 Placental magnetic resonance imaging in preterm preeclampsia: an observational cohort study","volume":"75","author":"Ho","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2021.08.027_bib46","first-page":"151","article-title":"Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for \u201cplacental hyperoxia\u201d in intrauterine growth restriction","volume":"79","author":"Khaliq","year":"1999","journal-title":"Lab Invest"},{"key":"10.1016\/j.ajog.2021.08.027_bib47","first-page":"451","article-title":"Placental pathology in relation to uterine artery Doppler findings in pregnancies with severe intrauterine growth restriction and abnormal umbilical artery Doppler changes","volume":"34","author":"Levytska","year":"2017","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2021.08.027_bib48","doi-asserted-by":"crossref","first-page":"296.e1","DOI":"10.1016\/j.ajog.2017.01.014","article-title":"Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial","volume":"216","author":"Groom","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib49","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/AOG.0000000000001673","article-title":"Enoxaparin and aspirin compared with aspirin alone to prevent placenta-mediated pregnancy complications: a randomized controlled trial","volume":"128","author":"Haddad","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib50","doi-asserted-by":"crossref","first-page":"363.e1","DOI":"10.1016\/j.ajog.2006.10.897","article-title":"Usefulness of a placental profile in high-risk pregnancies","volume":"196","author":"Toal","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib51","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1182\/blood-2011-07-319749","article-title":"Is heparin a placental anticoagulant in high-risk pregnancies?","volume":"118","author":"Kingdom","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ajog.2021.08.027_bib52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/AOG.0000000000002380","article-title":"Angiogenic factor profiles in pregnant women with a history of early-onset severe preeclampsia receiving low-molecular-weight heparin prophylaxis","volume":"131","author":"Lecarpentier","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.08.027_bib53","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/HYPERTENSIONAHA.115.06783","article-title":"Placental growth factor administration abolishes placental ischemia-induced hypertension","volume":"67","author":"Spradley","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2021.08.027_bib54","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/HYPERTENSIONAHA.120.15146","article-title":"Prediction of preeclampsia-related adverse outcomes with the sFlt-1 (soluble fms-Like tyrosine kinase 1)\/PlGF (placental growth factor)-Ratio in the Clinical Routine: a real-world study","volume":"77","author":"Dr\u00f6ge","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2021.08.027_bib55","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1538-7836.2011.04407.x","article-title":"Unfractionated heparin for second trimester placental insufficiency: a pilot randomized trial","volume":"9","author":"Kingdom","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ajog.2021.08.027_bib56","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/HYPERTENSIONAHA.113.01420","article-title":"Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy","volume":"62","author":"Burwick","year":"2013","journal-title":"Hypertension"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821009613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821009613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:34:04Z","timestamp":1757590444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937821009613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0002937821009613"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2021.08.027","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}